Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $3.2 million.

  • Assembly Biosciences' Non-Current Assets rose 5544.17% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.7 million, marking a year-over-year increase of 3395.8%. This contributed to the annual value of $3.7 million for FY2024, which is 2071.81% up from last year.
  • According to the latest figures from Q3 2025, Assembly Biosciences' Non-Current Assets is $3.2 million, which was up 5544.17% from $3.3 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Non-Current Assets ranged from a high of $60.8 million in Q3 2021 and a low of $2.0 million during Q3 2023
  • In the last 5 years, Assembly Biosciences' Non-Current Assets had a median value of $3.5 million in 2025 and averaged $16.1 million.
  • As far as peak fluctuations go, Assembly Biosciences' Non-Current Assets crashed by 8944.7% in 2023, and later surged by 5544.17% in 2025.
  • Over the past 5 years, Assembly Biosciences' Non-Current Assets (Quarter) stood at $36.9 million in 2021, then tumbled by 86.9% to $4.8 million in 2022, then tumbled by 37.1% to $3.0 million in 2023, then rose by 20.72% to $3.7 million in 2024, then dropped by 13.1% to $3.2 million in 2025.
  • Its Non-Current Assets stands at $3.2 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.5 million for Q1 2025.